The May 2019 Data Release includes data from human studies, model studies, and the following publication: Single-cell transcriptomic analysis of Alzheimer’s disease.

Human

  • The DiCAD study.This is a study to elucidate the mechanisms linking type 2 diabetes, cerebrovascular and Alzheimer’s disease. It is comprised of a longitudinal cohort of 200 middle-aged individuals from Northern Manhattan and complementary experiments in several models of mice (see the SUNYStrokeModel). Previously released from this study is clinical data, medications, cognitive tests, lab tests, and MRI and PET imaging, on a subset of individuals at baseline.

    This release adds:
    New APOE genotypes
    Additional clinical, Imaging and  lab tests that completes the baseline data on the cohort. Download new versions of updated files.

  • The ADMC_UPenn study. This is a new prospective longitudinal case-control study of AD and MCI. Participants in this study were recruited at the Penn Memory Center, Alzheimer’s Disease Clinical Center, Perelman School of Medicine, University of Pennsylvania, and the Maria de los Santos Health Center.

    This release includes:
    Bile Acids, Lipids, PDI, and metabolites measured on the p180 platform platform in plasma and serum. A subset of 127 CSF and plasma samples were obtained on the same day from 112 unique participants (51 AD, 18 MCI and 43 CN), and other traditional biomarker data. SeeClinical data on the cohort, and Protocols

  • The ROSMAP study. These are two longitudinal clinical-pathologic cohort study of aging and Alzheimer’s disease run from Rush University. A variety of genomic variants, bulk gene expression, epigenomics, proteomics and metabolomics has previously been released.

    This release adds:
    single nucleus RNAseq from 48 individuals as described in&nbsp
    Single-cell transcriptomic analysis of Alzheimer’s disease. Provided is raw and processed data.

Models

  • The EmoryDrosophilaTau model study. This is a drosophila model for the human tau and the R406W mutation. Previously released from this study is RNAseq and proteomics and a set of pooled genotypes.

    This release adds:
    21 RNAseq samples on the human MAPT R406W mutant MAPT “ELAV>Tau(R406W)”, and the Small ribonucleoprotein particle protein model “yw-;SmBMG/SmBMG”.

  • The SUNYStrokeModel study. This is the complementary model to the human DiCAD study. The SUNYStrokeModel is a comparison among diabetic, amyloidogenic, and AD/diabetic mice, with and without transient occlusion of the middle cerebral artery. Previously released from this study is behavioral assessments and electrophysiology data on a subset of the mice.

    This release includes:NewMicrovascular perfusion flow data, and additional Active Place Avoidance behavioral data, and LTP + sLFP electrophysiology, on db mice tested at ~10 months.

  • The APOE-TR study. This is a study of the human APOE-targeted replacement mouse models, which express each human APOE genotype (APOE2, APOE3 or APOE4) under the control of the mouse endogenous Apoe promoter. Previously released from this study is behavioral assessment and lab tests.

    This release adds:
    RNAseq from the cerebral cortex, and Metabolomics on serum generated on the p180 platform for a total set of data from 287 animals

  • The MODEL-AD_5XFAD study. This a study of a familial Alzheimer’s disease model expressing mutant human APP and PS1. The 5XFAD transgenic mice overexpress both mutant human APP with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) Familial Alzheimer’s Disease mutations and human PS1 harboring two FAD mutations, M146L and L286V. The data in this study are being released as part of MODEL-AD (Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease)consortium.

    This release includes:
    RNAseq on the cortex and hippocampus from 60 animals 4, 8 or 12 months of age.
    Behavioral dataon 100 animals assessed by open field, elevated plus-maze, rotarod, contextual fear conditioning, novel place and object and y-maze at 4, 8 or 12 months of age.
    Immunoassays on 68 animals at 4 or 8 months of age measured for Aβ, tau and inflammatory cytokines in hippocampus and cortex.
    Immunofluorescence on the hippocampus and cortex from 40 animals at 4 months of age
    Preclinical Testing Core Levetiracetam data
    PET with AV45 or FDG ligands on 157 animals at 6months of age treated with Levetiracetam.
    Autorad analysis on the same animals that received PET scans.

  • ThePharmacokinetic Study. Acute PK data from a single dose of levetiracetam dosed to animals at 6 months of age, and chronic PK data from animals receiving levetiracetam or placebo for 3 months.
    Metadata on individual animals and biosamples. See subfolder with detailed protocols.
    The MODEL-AD_hAbeta_KI study. This is a study of a novel knock-in mouse model, dubbed the hAb-KI line, in which the murine amyloid precursor protein gene was humanized at the Ab locus, then bred to homozygosity. The data in this study are being released as part of MODEL-AD (Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease) consortium.

    This release includes:
    RNAseq on the hippocampus from 32 littermate mice at 2 or 22 months of age.
    Metadata on the individual animals, biosamples, and the assay

  • The MODEL-AD_APOE4.Trem2.R47H study. This is a study of a double mutant strain carrying a humanized ApoE knock-in allele, and a knock-in point mutation in the mouse Trem2.The data in this study are being released as part of MODEL-AD (Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease) consortium.

    This release includes:RNAseq on the the left hemisphere of 144 animals at ~4, 8 or 14 months of age.
    Metadataon the individual animals, biosamples, and the assay.
    The MODEL-AD_APP/PS1 study consolidates data from two previous studies using the APP/PS1 model, a double transgenic mouse that expresses a chimeric mouse/human amyloid precursor protein and a mutant human presenilin 1. The data in this study are being released as part of MODEL-AD (Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease)consortium.

    This release adds:RNAseq on the left brain hemisphere from 82 mice at 2, 4, 5, or 6 months of age.
    Metadata on the individual animals, biosamples, and the assay.

Changes

  • The MODEL-AD_APP/PS1 study consolidates data from two previous studies using the APP/PS1 model (Jax_APPPS1 and Jax_B6J.APPPS1_PlaqueOnset) using a double transgenic mouse that expresses a chimeric mouse/human amyloid precursor protein and a mutant human presenilin 1. The data in this study are being released as part of MODEL-AD (Model Organism Development & Evaluation for Late-Onset Alzheimer’s Disease) consortium.

    This release includes:
    RNAseq on the left brain hemisphere from 82 mice at 2, 4, 5, or 6 months of age.
    Analysis. Differential expression and GO enrichment.
    Metadata on the individual animals, biosamples, and the assay.

  • The SUNYStrokeModel study.
    Metadata: See update to the mouse metadata format.
  • APOE-TR study.
    Metadata: See update to the mouse metadata format.
  • The EmoryDrosophilaTau model study.
  • Metadata: See updated files for biospecimens, RNAseq, and proteomics. There are 18 samples used to generate both proteomics and RNAseq, these are now matched in the biospecimen file.